Limits...
Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer.

Fujimoto N, Kubo T, Shinsaka H, Matsumoto M, Shimajiri S, Matsumoto T - BMC Urol (2011)

Bottom Line: Factors associated with pT0, which is regarded as serious cancer cell damage or elimination, were investigated.Of the 68 males, 24 (35.3%) were classified as pT0.No other clinical characteristics predicted conversion to pT0.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan. n-fuji@med.uoeh-u.ac.jp

ABSTRACT

Background: Primary androgen deprivation therapy (ADT) is a treatment option not only for advanced but also for localized prostate cancer. However, the appropriate duration for primary ADT for localized prostate cancer has not been defined and few studies have addressed this issue. In this study, we aimed to determine the appropriate duration of ADT for localized prostate cancer.

Methods: Sixty-eight consecutive patients with localized prostate cancer who underwent a prostatectomy following neoadjuvant ADT were retrospectively reviewed. Factors associated with pT0, which is regarded as serious cancer cell damage or elimination, were investigated.

Results: Of the 68 males, 24 (35.3%) were classified as pT0. The median duration of neoadjuvant ADT in the pT0 and non-pT0 groups was 9 months and 7.5 months, respectively (p = 0.022). The duration of neoadjuvant ADT from when PSA reached < 0.2 ng/ml to surgery was longer in the pT0 group than that in the non-pT0 group (median 5 months against 3 months, p = 0.011). pT0 was achieved in 5 of 6 patients (83.3%) who received ADT for ≥10 months after PSA reached < 0.2 ng/ml. No other clinical characteristics predicted conversion to pT0.

Conclusions: Continuous ADT for ≥10 months after PSA reached < 0.2 ng/ml induced serious prostate cancer cell damage in most patients (> 80%) and may be sufficient to treat localized prostate cancer.

Show MeSH

Related in: MedlinePlus

PSA progression-free survival in the pT0 and non-pT0 groups.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3116482&req=5

Figure 3: PSA progression-free survival in the pT0 and non-pT0 groups.

Mentions: With a median postoperative follow-up of 31 months (range, 4-114 months), PSA progression was observed in one (4.2%) and nine (20.5%) patients in the pT0 and non-pT0 groups, respectively. Patients in the pT0 group had a tendency for longer PSA progression-free survival, although the difference was not statistically significant (p = 0.062) (Figure 3). Of all patients, only one in the non-pT0 group clinically progressed and died of prostate cancer 55 months following surgery.


Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer.

Fujimoto N, Kubo T, Shinsaka H, Matsumoto M, Shimajiri S, Matsumoto T - BMC Urol (2011)

PSA progression-free survival in the pT0 and non-pT0 groups.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3116482&req=5

Figure 3: PSA progression-free survival in the pT0 and non-pT0 groups.
Mentions: With a median postoperative follow-up of 31 months (range, 4-114 months), PSA progression was observed in one (4.2%) and nine (20.5%) patients in the pT0 and non-pT0 groups, respectively. Patients in the pT0 group had a tendency for longer PSA progression-free survival, although the difference was not statistically significant (p = 0.062) (Figure 3). Of all patients, only one in the non-pT0 group clinically progressed and died of prostate cancer 55 months following surgery.

Bottom Line: Factors associated with pT0, which is regarded as serious cancer cell damage or elimination, were investigated.Of the 68 males, 24 (35.3%) were classified as pT0.No other clinical characteristics predicted conversion to pT0.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan. n-fuji@med.uoeh-u.ac.jp

ABSTRACT

Background: Primary androgen deprivation therapy (ADT) is a treatment option not only for advanced but also for localized prostate cancer. However, the appropriate duration for primary ADT for localized prostate cancer has not been defined and few studies have addressed this issue. In this study, we aimed to determine the appropriate duration of ADT for localized prostate cancer.

Methods: Sixty-eight consecutive patients with localized prostate cancer who underwent a prostatectomy following neoadjuvant ADT were retrospectively reviewed. Factors associated with pT0, which is regarded as serious cancer cell damage or elimination, were investigated.

Results: Of the 68 males, 24 (35.3%) were classified as pT0. The median duration of neoadjuvant ADT in the pT0 and non-pT0 groups was 9 months and 7.5 months, respectively (p = 0.022). The duration of neoadjuvant ADT from when PSA reached < 0.2 ng/ml to surgery was longer in the pT0 group than that in the non-pT0 group (median 5 months against 3 months, p = 0.011). pT0 was achieved in 5 of 6 patients (83.3%) who received ADT for ≥10 months after PSA reached < 0.2 ng/ml. No other clinical characteristics predicted conversion to pT0.

Conclusions: Continuous ADT for ≥10 months after PSA reached < 0.2 ng/ml induced serious prostate cancer cell damage in most patients (> 80%) and may be sufficient to treat localized prostate cancer.

Show MeSH
Related in: MedlinePlus